Skip to main content

Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





NTE001

Neurology
Mona Sazgar
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Epilepsy

Study Description

Subjects will undergo a single CT or MRI-guided intracerebral administration of human interneurons that secrete the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), into the temporal lobe region of the brain where the seizures are thought to arise. NRTX-1001 is intended to suppress the onset and spread of seizures. Safety, efficacy, tolerability, and effects on reducing seizure frequency and epilepsy disease symptoms will be assessed at regular intervals for 2 years after the administration of NRTX-1001. After the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 5, and then annual visits in years 6 through 15. Subjects will be placed on an immunosuppressant medication regimen for a duration of one year to partially suppress the subjects' immune system to promote the intended long-term persistence of NRTX-1001. This immunosuppressant medication is intended to be discontinued after the first year; however, the NRTX-1001 cells are intended to persist long-term.

Eligibility

Male or Female, age 18 to 75

Focal seizures, clinically defined as unilateral MTLE

Has failed to achieve seizure control despite adequate trials of at least 2 ASDs at appropriate doses

Currently on stable doses (at least 1 month prior to Screening) of approved ASDs

Single seizure focus confirmed within one hippocampus

Seizure frequency averages 4 or more per 28-day period, including at least 2 clinical focal seizures per 28-day period with objective manifestations or more severe types, over the 6 months prior to the Screening Visit. (Phase 1/2 only)

Disabling seizure frequency of 2 per 28-day period averaged over 3 months prior to the Screening visit and over a prospective 10-week baseline period prior to Randomization (Phase 3 Only)

Key

Epilepsy due to other medical conditions and/or progressive neurologic disease

Evidence of seizure focus outside of the hippocampus or evidence of seizures of non- focal origin.

Significant other medical conditions which would impair safe participation

History of status epilepticus in the 3 years prior to screening.

Primary or secondary immunodeficiency

Suicide attempts in the past year 3 years

Severe psychiatric disorders

Prior lobectomy or LITT procedure

MRI indicating potential malignant lesion

Pregnancy, or currently breastfeeding.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.